Page 16 - Tim Dyer News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Addex GABAB Positive Allosteric Modulator Demonstrates Promise in Alcohol Use Disorder Addex TherapeuticsFebruary 16, 2021 GMT Review from Linköping University Published in Alcohol and Alcoholism Journal Geneva, Switzerland, February 16, 2021 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that a review published in Alcohol and Alcoholism suggests that positive allos...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Addex to Present at the Baader Helvea Swiss Equities Conference Addex TherapeuticsJanuary 12, 2021 GMT Geneva, Switzerland, January 12, 2021 -   Addex Therapeutics  Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that Tim Dyer, Chief Executive Officer, is scheduled to participate in the virtual Baader Helvea Swiss Equities Conference taking place on January 13 – January 15, 2021. AD...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Addex Successfully Completes $11.5 Million Capital Increase Including Full Exercise of ... Addex TherapeuticsJanuary 11, 2021 GMT Geneva, Switzerland, January 11, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today the successful completion of the previously announced global offering of 6,900,000 shares (New Shares) (including 6,750,000 shares delivered in the form...

Geneva, Switzerland, January 7, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric...

Share: Geneva, Switzerland, December 14, 2020 – Addex Therapeutics Ltd (NASDAQ:ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development announced today that it has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) for a proposed underwritten public offering of shares, including those to be settled in the form of American Depositary Shares (ADSs). Each ADS represents the right to receive six shares of Addex.  The terms of the offering have not been determined, and the offering is subject to marke...